JP2024511137A5 - - Google Patents

Info

Publication number
JP2024511137A5
JP2024511137A5 JP2023558578A JP2023558578A JP2024511137A5 JP 2024511137 A5 JP2024511137 A5 JP 2024511137A5 JP 2023558578 A JP2023558578 A JP 2023558578A JP 2023558578 A JP2023558578 A JP 2023558578A JP 2024511137 A5 JP2024511137 A5 JP 2024511137A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
cdrl1
cdrl2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023558578A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511137A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/057555 external-priority patent/WO2022200389A1/en
Publication of JP2024511137A publication Critical patent/JP2024511137A/ja
Publication of JP2024511137A5 publication Critical patent/JP2024511137A5/ja
Pending legal-status Critical Current

Links

JP2023558578A 2021-03-22 2022-03-22 Cd47およびpd-l1を標的とする二重特異性抗体ならびにその使用方法 Pending JP2024511137A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163164329P 2021-03-22 2021-03-22
US63/164,329 2021-03-22
US202263317899P 2022-03-08 2022-03-08
US63/317,899 2022-03-08
PCT/EP2022/057555 WO2022200389A1 (en) 2021-03-22 2022-03-22 Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2024511137A JP2024511137A (ja) 2024-03-12
JP2024511137A5 true JP2024511137A5 (https=) 2025-03-31

Family

ID=81384718

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023558578A Pending JP2024511137A (ja) 2021-03-22 2022-03-22 Cd47およびpd-l1を標的とする二重特異性抗体ならびにその使用方法

Country Status (7)

Country Link
US (1) US12448444B2 (https=)
EP (1) EP4314065A1 (https=)
JP (1) JP2024511137A (https=)
AU (1) AU2022245196A1 (https=)
CA (1) CA3212056A1 (https=)
IL (1) IL305827A (https=)
WO (1) WO2022200389A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12448444B2 (en) 2021-03-22 2025-10-21 Novimmune Sa Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereof
IL305828A (en) * 2021-03-22 2023-11-01 Novimmune Sa Bispecific antibodies targeting CD47 and PD-L1 and methods of using them
EP4493592A1 (en) 2022-03-14 2025-01-22 LamKap Bio gamma AG Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells
US20240254223A1 (en) * 2022-09-02 2024-08-01 Novimmune Sa Reciprocally masked antibody-cytokine fusion proteins and methods of use thereof
US20240254234A1 (en) 2022-10-21 2024-08-01 Novimmune Sa PD-L1xCD28 BISPECIFIC ANTIBODIES FOR IMMUNE CHECKPOINT-DEPENDENT T CELL ACTIVATION
WO2025133389A1 (en) * 2023-12-22 2025-06-26 Numab Therapeutics AG Antibody binding domains having specificity for lilrb2
EP4574844A1 (en) * 2023-12-22 2025-06-25 Numab Therapeutics AG Multispecific antibodies having specificity for cd47 and pdl1

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0279862B1 (en) 1986-08-28 1993-11-03 Teijin Limited Cytocidal antibody complex and process for its preparation
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
EP0745134A1 (en) 1994-02-22 1996-12-04 Danafarber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
EP1810979B1 (en) 2004-09-22 2012-06-20 Kyowa Hakko Kirin Co., Ltd. STABILIZED HUMAN IgG4 ANTIBODIES
CN102459591B (zh) 2009-05-20 2015-05-13 诺维莫尼公司 合成性的多肽文库以及用于建立具有天然多样性的多肽变体的方法
WO2011084255A2 (en) 2009-12-17 2011-07-14 Novimmune S.A. Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants
CN103261220B (zh) 2010-08-16 2016-06-15 诺夫免疫股份有限公司 用于生成多特异性和多价抗体的方法
TWI452136B (zh) 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
PT2768857T (pt) 2011-10-19 2020-01-27 Novimmune Sa Métodos para purificar anticorpos
DK3725807T3 (da) 2012-12-03 2026-01-12 Novimmune Sa Anti-cd47 antistoffer og fremgangsmåder til anvendelse deraf
US9111624B2 (en) 2013-03-22 2015-08-18 Katsuyuki Fujita Semiconductor memory device
US11260117B2 (en) 2017-05-26 2022-03-01 Novimmune Sa Anti-CD47 x anti-mesothelin antibodies and methods of use thereof
AU2018303254B2 (en) * 2017-07-21 2025-05-29 Novimmune Sa Generating multispecific antibody mixtures and methods of uses thereof
EP3722322A4 (en) * 2017-12-04 2021-09-15 Beijing Hanmi Pharmaceutical Co., Ltd. ANTI-PD-L1 / ANTI-CD47 BISPECIFIC ANTIBODY HAVING A NATURAL ANTIBODY STRUCTURE AND IN THE FORM OF A HETERODIMER, AND ASSOCIATED PREPARATION
EP3802599B1 (en) 2018-06-03 2023-12-20 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
US12448444B2 (en) 2021-03-22 2025-10-21 Novimmune Sa Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereof
IL305828A (en) 2021-03-22 2023-11-01 Novimmune Sa Bispecific antibodies targeting CD47 and PD-L1 and methods of using them
KR20240165995A (ko) 2022-03-24 2024-11-25 길리애드 사이언시즈, 인코포레이티드 Trop-2 발현 암의 치료를 위한 병용요법
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法

Similar Documents

Publication Publication Date Title
JP2024511137A5 (https=)
JP2024512574A5 (https=)
JP2020526478A5 (https=)
CN101939336B (zh) Axl抗体
ES2577292T3 (es) Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
IL302078A (en) Anti-CCR8 monoclonal antibodies and their uses
JP2013506622A5 (https=)
US9994632B2 (en) Humanized or affinity-matured anti Ang-2 antibody and uses thereof
JP2025092589A5 (https=)
JP2020502271A5 (https=)
TW201011047A (en) Multispecific antibodies
JP2019509737A5 (https=)
JP2017535257A5 (https=)
JP2018503365A5 (https=)
JP2016510002A5 (https=)
JP2012532851A5 (https=)
JP2022509156A5 (https=)
JP2023133432A5 (https=)
JP2024102055A5 (https=)
JP2023509214A5 (https=)
JP2021511387A5 (https=)
JP2025507817A5 (https=)
JP2023509215A5 (https=)
JP2023549316A5 (https=)
JP2023517754A5 (https=)